Yesong Choe
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Yesong Choe has a total of 4 co-authors. Here are the top co-authors by number of shared publications:
Minjung Kho
Graduate School of Data Science, Seoul National University , Seoul
1 shared publicationSanghack Lee
Graduate School of Data Science, Seoul National University , Seoul
1 shared publication- Seunggeun Lee
Graduate School of Data Science, Seoul National University, Republic of Korea
1 shared publication Yeahoon Kwon
Graduate School of Data Science, Seoul National University , Seoul
1 shared publication
Latest Publications
- 29 September 2026
- Published by Oxford University Press (OUP) in American Journal of Epidemiology
Event-time regression discontinuity for biomedical data: local average treatment effect among the treated estimation and covariate distribution tests
Estimating causal effects of drugs on clinical biomarkers is often infeasible through randomized trials, while observational data require designs that approximate experimental conditions. Using linked UK Biobank records collected during 2006-2013, we develop an event-time regression discontinuity framework for settings in which prescription records are longitudinal but biomarkers are measured cross-sectionally. A surrogate running variable aligns individuals by the interval between biomarker measurement and the first recorded prescription, comparing eventual users measured shortly before vs after that date. Under continuity assumptions, this identifies a local average treatment effect among the treated. We apply distributional covariate-balance diagnostics, robust bias-corrected inference, and parsimonious covariate adjustment. Statin analyses show a local downward low-density lipoprotein discontinuity around the first recorded prescription date, with direction and statistical significance robust across bias-corrected inference, bandwidths, and donut specifications. However, the running-variable density test is significant and donut estimates vary from −1.00 to −1.72 mmol/L, indicating residual uncertainty about local comparability. The metformin–HbA1c example is less stable: a sizeable parametric local-linear reduction is not corroborated under robust bias-corrected inference. Event-time regression discontinuity offers potential for pharmacovigilance and real-world causal inference in linked health databases, but conclusions depend on explicit local timing-exogeneity and continuity assumptions.
- 29 September 2026
- Published by Oxford University Press (OUP) in American Journal of Epidemiology
Event-time regression discontinuity for biomedical data: local average treatment effect among the treated estimation and covariate distribution tests
Estimating causal effects of drugs on clinical biomarkers is often infeasible through randomized trials, while observational data require designs that approximate experimental conditions. Using linked UK Biobank records collected during 2006-2013, we develop an event-time regression discontinuity framework for settings in which prescription records are longitudinal but biomarkers are measured cross-sectionally. A surrogate running variable aligns individuals by the interval between biomarker measurement and the first recorded prescription, comparing eventual users measured shortly before vs after that date. Under continuity assumptions, this identifies a local average treatment effect among the treated. We apply distributional covariate-balance diagnostics, robust bias-corrected inference, and parsimonious covariate adjustment. Statin analyses show a local downward low-density lipoprotein discontinuity around the first recorded prescription date, with direction and statistical significance robust across bias-corrected inference, bandwidths, and donut specifications. However, the running-variable density test is significant and donut estimates vary from −1.00 to −1.72 mmol/L, indicating residual uncertainty about local comparability. The metformin–HbA1c example is less stable: a sizeable parametric local-linear reduction is not corroborated under robust bias-corrected inference. Event-time regression discontinuity offers potential for pharmacovigilance and real-world causal inference in linked health databases, but conclusions depend on explicit local timing-exogeneity and continuity assumptions.